Victory Capital Management’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$309M Sell
627,704
-147,703
-19% -$80.2M 0.2% 117
2025
Q4
$449M Sell
775,407
-63,965
-8% -$36.2M 0.25% 78
2025
Q3
$328M Buy
839,372
+19,316
+2% +$8.99M 0.19% 117
2025
Q2
$336M Buy
820,056
+649,019
+379% +$271M 0.22% 108
2025
Q1
$85.1M Buy
171,037
+911
+0.5% +$493K 0.09% 277
2024
Q4
$88.5M Sell
170,126
-5,461
-3% -$3M 0.09% 260
2024
Q3
$109M Sell
175,587
-6,167
-3% -$3.65M 0.1% 225
2024
Q2
$101M Buy
181,754
+905
+0.5% +$518K 0.1% 240
2024
Q1
$105M Sell
180,849
-2,105
-1% -$1.18M 0.1% 249
2023
Q4
$97.1M Sell
182,954
-78,006
-30% -$37.8M 0.1% 248
2023
Q3
$132M Sell
260,960
-15,849
-6% -$8.45M 0.15% 146
2023
Q2
$144M Sell
276,809
-10,790
-4% -$5.82M 0.16% 137
2023
Q1
$166M Sell
287,599
-29,216
-9% -$16.5M 0.19% 117
2022
Q4
$174M Sell
316,815
-21,656
-6% -$11.5M 0.2% 116
2022
Q3
$172M Buy
338,471
+11,655
+4% +$6.52M 0.2% 113
2022
Q2
$178M Sell
326,816
-8,688
-3% -$4.78M 0.2% 119
2022
Q1
$191M Sell
335,504
-6,046
-2% -$3.47M 0.19% 119
2021
Q4
$228M Buy
341,550
+27,805
+9% +$17.4M 0.21% 109
2021
Q3
$179M Sell
313,745
-17,790
-5% -$9.76M 0.18% 137
2021
Q2
$167M Sell
331,535
-3,597
-1% -$1.7M 0.16% 150
2021
Q1
$153M Buy
335,132
+131,829
+65% +$62.9M 0.16% 150
2020
Q4
$94.7M Buy
203,303
+35,494
+21% +$16.6M 0.11% 276
2020
Q3
$74.1M Buy
167,809
+31,135
+23% +$12.9M 0.1% 298
2020
Q2
$49.5M Sell
136,674
-209,876
-61% -$70.3M 0.07% 426
2020
Q1
$98.3M Buy
346,550
+182,203
+111% +$57.5M 0.08% 344
2019
Q4
$53.4M Buy
164,347
+12,737
+8% +$3.86M 0.06% 448
2019
Q3
$44.2M Buy
151,610
+129,817
+596% +$37.2M 0.06% 495
2019
Q2
$6.4M Buy
21,793
+1,568
+8% +$432K 0.01% 856
2019
Q1
$5.54M Sell
20,225
-4,874
-19% -$1.21M 0.01% 819
2018
Q4
$5.62M Sell
25,099
-109
-0.4% -$25.6K 0.01% 806
2018
Q3
$6.15M Buy
25,208
+2,225
+10% +$512K 0.01% 824
2018
Q2
$4.76M Buy
22,983
+1,826
+9% +$388K 0.01% 853
2018
Q1
$4.37M Buy
21,157
+1,234
+6% +$259K 0.01% 848
2017
Q4
$3.78M Buy
19,923
+1,248
+7% +$239K 0.01% 865
2017
Q3
$3.53M Buy
18,675
+575
+3% +$104K 0.01% 862
2017
Q2
$3.16M Buy
18,100
+1,645
+10% +$276K 0.01% 872
2017
Q1
$2.53M Buy
16,455
+1,800
+12% +$275K 0.01% 898
2016
Q4
$2.07M Buy
14,655
+731
+5% +$108K 0.01% 918
2016
Q3
$2.21M Buy
13,924
+3,155
+29% +$486K 0.01% 873
2016
Q2
$1.59M Buy
10,769
+91
+0.9% +$13.4K 0.01% 692
2016
Q1
$1.51M Sell
10,678
-1,375
-11% -$184K 0.01% 707
2015
Q4
$1.71M Buy
12,053
+5,532
+85% +$738K 0.01% 682
2015
Q3
$797K Buy
6,521
+541
+9% +$70.5K ﹤0.01% 807
2015
Q2
$781K Buy
5,980
+4,570
+324% +$596K ﹤0.01% 850
2015
Q1
$189K Sell
1,410
-26,457
-95% -$3.41M ﹤0.01% 783
2014
Q4
$3.49M Sell
27,867
-2,803
-9% -$341K 0.01% 587
2014
Q3
$3.73M Sell
30,670
-3,840
-11% -$467K 0.03% 367
2014
Q2
$4.07M Buy
34,510
+33,150
+2,438% +$3.9M 0.03% 371
2014
Q1
$164K Buy
1,360
+10
+0.7% +$1.19K ﹤0.01% 632
2013
Q4
$150K Buy
1,350
+9
+0.7% +$895 ﹤0.01% 667
2013
Q3
$123K Buy
+1,341
New +$121K ﹤0.01% 713

Other funds holding TMO

Victory Capital Management's TMO Position: Q1 2026 in Review

Victory Capital Management reduced its Thermo Fisher Scientific (TMO) stake by 19% in Q1 2026, selling an estimated $80.2M and leaving 627,704 shares worth $309M. The position accounts for 0.2% of the portfolio, ranked #117.

Victory Capital Management first reported a position in TMO in Q3 2013 and has held it in 51 quarters since. The position peaked at $449M in Q4 2025. 2,587 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

  • Victory Capital Management held 627,704 shares of Thermo Fisher Scientific worth $309M as of Q1 2026.
  • Victory Capital Management sold 147,703 Thermo Fisher Scientific shares in Q1 2026, an estimated $80.2M.
  • Thermo Fisher Scientific made up 0.2% of Victory Capital Management's portfolio in Q1 2026, its #117 holding.
  • Victory Capital Management first reported a position in Thermo Fisher Scientific in Q3 2013 and has held it in 51 quarters since.
  • Victory Capital Management's Thermo Fisher Scientific position peaked at $449M in Q4 2025.
  • 2,587 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.